Lung Cancer Statistics

Hanmi Pharm's Poziotinib Proves Effective for Rare Non-small-cell Lung Cancer

8 hours 9 min ago
Currently, about 10 percent of non-small-cell lung cancer patients with EGFR mutation suffer from exon 20 mutation. However, no cure has been ...

Indigenous smoking rates cut down

Wed, 10/18/2017 - 21:30
However the lag between smoking and its associated cancer mortality ... between smoking and the onset of diseases such as lung cancer,” he said.

Bonnie J. Addario Lung Cancer Foundation and International Association for the Study of Lung ...

Wed, 10/18/2017 - 19:48
Lung adenocarcinomas are a leading cause of cancer mortality and are typically detected at a late stage. To catch lung cancer early, annual CT scans ...

Ado-Trastuzumab Emtansine Shows Activity in HER2-Mutated, Amplified Lung Cancer

Wed, 10/18/2017 - 16:15
HER2 mutations and amplifications are known oncogenic drivers that occur in about 2% of lung cancer cases, but clinical trials of HER2 kinase ...

New Data Shows Potential of Entrectinib in NSCLC

Wed, 10/18/2017 - 14:00
This morning at the International Association for the Study of Lung Cancer (IASLC) ... in patients with ROS1-positive non-small cell lung cancer (NSCLC). ... demonstrated a 78% confirmed overall response rate (ORR) by Investigator ...

Luminespib May Be Effective in NSCLC With EGFR Exon 20 Insertion Mutation

Wed, 10/18/2017 - 13:26
Exon 20 mutations account for 4% to 10% of EGFR mutations in NSCLC and ... The overall response rate (ORR) was 17%, with 4 patients displaying a ...

Pembrolizumab After Locally Ablative Therapy May Be Beneficial in Metastatic NSCLC

Wed, 10/18/2017 - 13:26
Ninety percent of patients in the study were current or former smokers. The most frequently observed sites of metastasis were lung, brain, and bone.

Liquid Biopsies Detect Unknown Driver Mutations in Advanced NSCLC

Wed, 10/18/2017 - 13:26
Liquid Biopsies Detect Unknown Driver Mutations in Advanced NSCLC ... NGS detected plasma ctDNA in 46 (60%) patients, with detection rates of 46% ... Liquid biopsy in the lung cancer clinic: a prospective study of plasma DNA ...

Lung Cancer Treatment in North America: Recent Advances and Future Promises

Wed, 10/18/2017 - 13:26
Lung Cancer Treatment in North America: Recent Advances and Future ... after, or during [chemotherapy/radiotherapy] and will improve cure rates.”.

CT lung cancer screening combined with smoking cessation is worth expense

Wed, 10/18/2017 - 13:15
CT lung cancer screening combined with smoking cessation is worth expense ... These interventions were shown to decrease mortality rates while ...

Investors Race to Buy Spectrum Pharmaceuticals, Inc. (SPPI) Shares; Here's Why

Wed, 10/18/2017 - 12:41
“These data are remarkable for NSCLC patients with exon 20 insertion ... “These patients currently have a poor prognosis, single-digit response rate ...

Smoking cessation appears cost-effective for lung cancer screening program

Wed, 10/18/2017 - 11:00
“We know that lung cancer screening can reduce lung cancer mortality but what would be the impact of introducing smoking cessation in terms of cost ...

Online Only

Wed, 10/18/2017 - 10:15
Yokohama, Japan—As non-small cell lung cancer (NSCLC) survival rates have increased over time, new research sheds light on how NSCLC ...

(BPRW) OCTOBER: NATIONAL BREAST CANCER AWARENESS MONTH

Wed, 10/18/2017 - 09:41
More statistics indicate that 1 in 8 women in the United States develops ... the highest death rate of any other type of cancer, other than lung cancer.

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

Wed, 10/18/2017 - 09:30
Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers ... Conference on Lung Cancer in Japan, showed an objective response rate of 73%. ... or metastatic cholangiocarcinoma and gallbladder adenocarcinoma.

Community engagement interventions may reduce disparities in lung cancer outcomes among ...

Wed, 10/18/2017 - 09:07
Significant lung cancer survival rate disparities exist among racial and ethnic minorities, the medically underserved and within certain regions.

Ignyta's entrectinib shows 78% response rate in certain patients with advanced lung cancer; shares ...

Wed, 10/18/2017 - 08:22
Ignyta (NASDAQ:RXDX) is up 30% premarket on robust volume in response its announcement of updated clinical data on lung cancer candidate ...

Merck's Keytruda doubles survival over chemo in lung cancer study

Wed, 10/18/2017 - 07:03
Merck's Keytruda doubles survival over chemo in lung cancer study ... Overall response rate for the KEYTRUDA cohort was 45.5% compared to 29.8% ...

Merck's KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival Compared to ...

Wed, 10/18/2017 - 06:41
The study included patients with squamous and nonsquamous NSCLC with no ... Other secondary endpoints include overall response rate (ORR) and safety. ... The two main types of lung cancer are non-small cell and small cell.

Merck (MRK) Says KEYTRUDA More Than Doubled Median Overall Survival Compared to ...

Wed, 10/18/2017 - 06:41
The study included patients with squamous and nonsquamous NSCLC with no ... The 24-month OS rate was 51.5 percent in the KEYTRUDA group ...

Pages